Deena Beasleyediting News Today

(Reuters) -Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales. For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but lowered its earnings outlook to include the recent charge as well as incremental expenses related to the CymaBay deal. Wall Street analyst...

By Deena Beasley (Reuters) -Gilead Sciences Inc on Thursday posted a higher-than-expected third-quarter profit despite lower sales of its COVID-19 ant...

-Early trial data on Amgen Incs Lumakras was released on Tuesday by the World Conference on Lung Cancer , but meeting organizers decided to hold until Aug. 7 results from a highly anticipated study...